Ablynx, a Sanofi company, is a clinical-stage biopharmaceutical company dedicated to creating new medicines which will make a real difference to society.

The Company has more than 45 proprietary and partnered product candidates in development for the treatment of a wide range of diseases, including inflammation, haematology, respiratory disease, immuno-oncology and oncology. (status August 2018)

Eight Nanobodies are currently in clinical development and the first product (caplacizumab for the treatment of acquired TTP) has been launched in Germany in October 2018.